D. Shames

发表

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

Thomas D. Wu, R. Gentleman, R. Neve, 2012, Genome research.

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

A. Sparks, M. Kennemer, K. Pant, 2010, Nature.

A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies

W. Gerald, C. Perou, J. Pollack, 2006, PLoS medicine.

DNA methylation in health, disease, and cancer.

J. Minna, A. Gazdar, D. Shames, 2007, Current molecular medicine.

Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.

J. Pollack, J. Minna, I. Wistuba, 2010, Cancer research.

A Translational View of the Molecular Pathogenesis of Lung Cancer

J. Minna, A. Gazdar, Mitsuo Sato, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Re-identification of Affymetrix HG-U133 probe sequences using BLAST alignment and its application to distinguishing lung cancer from normal lung expression profiles

W. Gerald, J. Minna, D. Beer, 2006 .

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

M. Socinski, F. Cappuzzo, T. Mok, 2022, Journal for ImmunoTherapy of Cancer.

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

D. Shames, M. Das Thakur, R. Bruno, 2020, Pharmacology research & perspectives.

MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC

P. Hegde, Keunchil Park, D. Gandara, 2017 .

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

Laura A. Sullivan, C. Roland, D. Shames, 2009, Molecular Cancer Therapeutics.

Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.

T. Mok, S. Peters, F. de Marinis, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.

A. Raffo, D. Shames, C. Stein, 2002, Cancer research.

Relationship Between Neuroendocrine and Immune Gene Expression in Small Cell Lung Cancer

Yuan Zhang, R. Deberardinis, J. Minna, 2020, bioRxiv.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

Metabolic diversity in human non-small cell lung cancer

B. Faubert, R. Deberardinis, J. Minna, 2014, bioRxiv.

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

D. Gandara, S. Yaung, D. Shames, 2021, JCO precision oncology.

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.

T. Mok, Yi-long Wu, S. Thongprasert, 2016, Lung cancer.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

H. Koeppen, L. Hart, J. Bendell, 2017, The oncologist.

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, M. Socinski, V. Velcheti, 2022, Nature Medicine.

The evolving genomic classification of lung cancer

I. Wistuba, D. Shames, 2013, The Journal of pathology.

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Keunchil Park, T. Mok, Yi-long Wu, 2018, Lung cancer.

Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups

M. Socinski, J. Mazières, D. Shames, 2018, Clinical Trials.

Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

Kimberly Walter, David S. Shames, Peter W. Laird, 2016, Nature Biotechnology.

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

F. Hirsch, Keunchil Park, D. Gandara, 2021, Clinical lung cancer.

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials

D. Shames, M. Mccleland, P. Norman, 2021, Journal for ImmunoTherapy of Cancer.

28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology

D. Shames, M. Mccleland, P. Norman, 2021, Journal for ImmunoTherapy of Cancer.

Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

P. Hegde, T. Mok, D. Gandara, 2017, Pneumologie.

Metabolic diversity in human non-small cell lung cancer

B. Faubert, R. Deberardinis, J. Minna, 2014, bioRxiv.

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

M. Kris, V. Rusch, I. Wistuba, 2022, Nature Medicine.

NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition

J. Minna, I. Wistuba, L. Girard, 2013, Oncogenesis.

831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research

Thomas W. Campbell, D. Shames, M. Mccleland, 2021, Journal for ImmunoTherapy of Cancer.

Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).

M. Shah, Yoon-Koo Kang, D. Shames, 2015 .

METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).

M. Shah, Y. Bang, F. Lordick, 2015 .

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

M. Shah, Yoon-Koo Kang, I. Tan, 2016, The oncologist.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

D. Gandara, Melissa L. Johnson, S. Novello, 2022, Nature Medicine.

IP6K2 is a client for HSP90 and a target for cancer therapeutics development

J. Minna, D. Shames, 2008, Proceedings of the National Academy of Sciences.

roid Receptor Coactivator-3 Expression in Lung cer and Its Role in the Regulation of Cancer Cell

J. Pollack, J. Minna, I. Wistuba, 2010 .

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

J. Hainsworth, C. Swanton, F. Meric-Bernstam, 2021, Cancer discovery.

Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.

P. Hegde, I. Wistuba, F. Hirsch, 2015 .

Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

R. Deberardinis, J. Minna, I. Wistuba, 2021, Communications biology.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

J. Minna, A. Gazdar, J. Soh, 2013, Oncogene.

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.

B. Nabet, J. Giltnane, L. Rangell, 2022, Cancer cell.

Molecular determinants of response to PD-L1 blockade across tumor types

P. Hegde, T. Powles, E. Sokol, 2021, Nature Communications.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Jacob Silterra, David S. Shames, Craig A. Cummings, 2018, Nature Medicine.

Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

R. Bourgon, P. Hegde, T. Powles, 2018 .

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

T. Powles, P. Albers, H. Nishiyama, 2021, Nature.

Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas

Li Li, William F. Forrest, Laura Deming, 2012, Clinical Cancer Research.

Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs

D. Corey, J. Minna, D. Shames, 2005, Nature chemical biology.

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.

Leonard D. Goldstein, R. Gentleman, F. Gnad, 2016, Cell reports.

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

P. Robson, Jing Wang, J. Minna, 2021, Cancer cell.

Involvement of AGO1 and AGO2 in mammalian transcriptional silencing

D. Corey, J. Minna, D. Shames, 2006, Nature Structural &Molecular Biology.

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

J. Settleman, T. Wilson, D. Shames, 2011, Cancer cell.

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

Calum MacAulay, John D. Minna, David S. Shames, 2009, PloS one.

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer

Michael Q. Zhang, Wei Zhang, Xiaotu Ma, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

A. Mansfield, T. Mok, Melissa L. Johnson, 2018, The New England journal of medicine.

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Cancer Immunology, Immunotherapy.

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

J. Roth, S. Swisher, V. Miller, 2021, Journal for ImmunoTherapy of Cancer.

miRNAs in Transitions

Y. Hasegawa, Mitsuo Sato, D. Shames, 2015 .

Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

R. Deberardinis, J. Minna, I. Wistuba, 2021, Communications Biology.

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Robert Gentleman, Florian Gnad, John D. Minna, 2012, Nature Genetics.

Methods for detecting DNA methylation in tumors: from bench to bedside.

J. Minna, A. Gazdar, D. Shames, 2007, Cancer letters.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

A. Warth, A. Marchetti, L. Bubendorf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice.

J. Fleming, D. Shames, R. Brekken, 2008, Cancer research.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

G. Hampton, P. Hegde, I. Wistuba, 2018, Proceedings of the National Academy of Sciences.

CDKN 2 A / p 16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non – Small-Cell Lung Cancer

Michael Q. Zhang, S. Hanash, W. Lam, 2013 .

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

G. Hampton, J. Fridlyand, J. Spoerke, 2012, Clinical Cancer Research.

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer

G. Hampton, R. Bourgon, K. Walter, 2012, Clinical Cancer Research.

Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

J. Minna, J. Soh, L. Girard, 2011, Molecular Cancer Therapeutics.

Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

J. Minna, L. Girard, M. Peyton, 2006, Cancer research.

Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells

J. Minna, L. Girard, M. Peyton, 2006 .

NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM

J. Minna, I. Wistuba, L. Girard, 2013, Proceedings of the National Academy of Sciences.

Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations

John D. Minna, David S. Shames, Yang Xie, 2013, Molecular Cancer Research.

Oncogenes and Tumor Suppressors Human Lung Epithelial Cells Progressed to Malignancy through Speci fi c Oncogenic Manipulations

J. Minna, I. Wistuba, A. Gazdar, 2013 .

Metabolic diversity in human non-small cell lung cancer

B. Faubert, R. Deberardinis, J. Minna, 2014, bioRxiv.

Methylation and Gene Silencing of the Ras-Related GTPase Gene in Lung and Breast Cancers

J. Minna, A. Gazdar, N. Sunaga, 2007, Annals of Surgical Oncology.

Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.

K. O'Byrne, T. Mok, M. Edelman, 2014 .

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

I. Wistuba, J. Zha, L. Rangell, 2014, Clinical Cancer Research.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

A. Jimeno, M. Hidalgo, J. Baselga, 2015, Clinical Cancer Research.

The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma

J. Minna, A. Gazdar, H. Osada, 2012, International journal of cancer.

Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer

J. Minna, L. Girard, A. Gazdar, 2012, International journal of cancer.

Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells

J. Minna, L. Girard, A. Gazdar, 2011, Cancer science.

sIR: siRNA Information Resource, a web-based tool for siRNA sequence design and analysis and an open access siRNA database

Michael A. White, John D. Minna, David S. Shames, 2007, BMC Bioinformatics.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Pan Tong, John V Heymach, Abena B. Redwood, 2017, Cancer research.

DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers

J. Minna, A. Gazdar, E. Frenkel, 2013, British Journal of Cancer.

DNA methylation-associated inactivation of TGFβ-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers

J. Minna, A. Gazdar, E. Frenkel, 2005, British journal of cancer.

Emerging evidence of epithelial‐to‐mesenchymal transition in lung carcinogenesis

Y. Hasegawa, Mitsuo Sato, D. Shames, 2012, Respirology.

Biological Subsets of Non – Small Cell Lung Cancer

G. Hampton, R. Bourgon, K. Walter, 2012 .

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

D. Shames, Miho Suzuki, N. Patil, 2021, Scientific Reports.

102PAnalytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)

D. Lipson, C. Cummings, C. Malboeuf, 2017 .

OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

G. Hampton, P. Hegde, G. Frampton, 2017 .

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

T. Mok, Yi-long Wu, S. Thongprasert, 2015, Clinical Cancer Research.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

A. Warth, A. Marchetti, L. Bubendorf, 2017, Lung cancer.

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

K. O'Byrne, M. Edelman, L. Paz-Ares, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Yulei N. Wang, E. Felip, D. Gerber, 2019, Clinical Cancer Research.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Federico Cappuzzo, Paul Delmar, Tudor Ciuleanu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells.

J. Minna, S. Toyooka, A. Gazdar, 2004, Cancer research.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

L. Recht, T. Mikkelsen, M. Weller, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

523 Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade

C. Rudin, J. Minna, B. Nabet, 2022, Regular and Young Investigator Award Abstracts.

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

R. Bourgon, K. Walter, T. Pham, 2013, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Loss of NAPRT 1 Expression by Tumor-Speci fi c Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

R. Bourgon, H. Koeppen, P. Haverty, 2013 .

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC

M. Kris, P. Bunn, D. Kwiatkowski, 2021, Annals of Oncology.

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial

M. Shah, Y. Bang, F. Lordick, 2017, JAMA oncology.

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

M. Socinski, D. Lipson, D. Fabrizio, 2023, Nature Medicine.

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.

V. Valero, T. Wilson, M. Campone, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Machine learning-based identification of predictive features of the tumor micro-environment and vasculature in NSCLC patients using the IMpower150 study.

A. Khosla, J. Fridlyand, A. Beck, 2020 .

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients

C. Marquette, D. Shames, E. Selva, 2017, Oncotarget.

A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).

David S. Shames, David E. Gerber, Jeffrey R. Infante, 2013 .

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

M. Socinski, V. Velcheti, D. Shames, 2019, Annals of Oncology.

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

M. Kris, V. Rusch, I. Wistuba, 2021 .

1383TiPBlood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC

Edward S. Kim, M. Socinski, T. Mok, 2017 .

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

David S. Shames, Matthew D. Hellmann, Garrett M. Frampton, 2016 .

Abstract 1750: Analysis of non-metastatic HCC patient tumors revealed the significance of cell cycle regulation and tumor immunity in association with overall survival and identified clinically relevant druggable targets

G. Hampton, L. Amler, Bonnie Liu, 2017 .

MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachment

J. Minna, L. Girard, T. Dragani, 2010, Molecular Cancer.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer

Paul Delmar, F. Hirsch, F. Shepherd, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).

M. Socinski, V. Velcheti, D. Fabrizio, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab

D. Lipson, C. Cummings, C. Malboeuf, 2018, Immunology.

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.

Edward S. Kim, M. Socinski, V. Velcheti, 2018 .

RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.

O. Olopade, J. Minna, Xian-Jin Xie, 2008, Cancer research.

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

L. Sequist, A. Chiang, S. Gettinger, 2016 .

A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

L. Hart, J. Bendell, D. Shames, 2015 .

1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations

M. Socinski, T. Mok, D. Shames, 2020 .

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations

F. Cappuzzo, T. Mok, O. Spleiss, 2016 .

An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study

D. Gandara, S. Yaung, D. Shames, 2019, Annals of Oncology.

Molecular pathogenesis of lung cancer with translation to the clinic: M10-01

K. Coombes, S. Lam, J. Minna, 2007 .

3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

A. Warth, A. Marchetti, L. Bubendorf, 2015 .

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

G. Hampton, K. Walter, J. Settleman, 2013, PloS one.

Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort

T. Mok, R. Dziadziuszko, D. Shames, 2019, Annals of Oncology.

DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers

J. Minna, A. Gazdar, E. Frenkel, 2013, British Journal of Cancer.

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

B. Faubert, R. Deberardinis, J. Minna, 2015, bioRxiv.

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

G. Hampton, J. Fridlyand, J. Spoerke, 2012, Clinical Cancer Research.

Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas

W. Forrest, Leslie B. Lee, A. Adler, 2012, Clinical Cancer Research.

PS01.54: Evaluation of Novel Blood‐Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B‐F1RST): Topic: Medical Oncology

M. Socinski, V. Velcheti, S. Dakhil, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Cancer Immunology, Immunotherapy.

Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.

M. Socinski, D. Shames, M. Reck, 2023, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

B. Nabet, E. Felip, D. Shames, 2024, Nature.

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

M. Socinski, D. Shames, O. Gjoerup, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

P. Hegde, I. Wistuba, S. Gettinger, 2015 .

Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer

Yulei N. Wang, Y. Guan, D. Shames, 2015 .